CLDX•benzinga•
Goldman Sachs Maintains Neutral on Celldex Therapeutics, Lowers Price Target to $31
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 9, 2025 by benzinga